450 related articles for article (PubMed ID: 27687593)
1. CARP-1 functional mimetics are novel inhibitors of drug-resistant triple negative breast cancers.
Cheriyan VT; Muthu M; Patel K; Sekhar S; Rajeswaran W; Larsen SD; Polin L; Levi E; Singh M; Rishi AK
Oncotarget; 2016 Nov; 7(45):73370-73388. PubMed ID: 27687593
[TBL] [Abstract][Full Text] [Related]
2. A CARP-1 functional mimetic compound is synergistic with BRAF-targeting in non-small cell lung cancers.
Cheriyan VT; Alsaab H; Sekhar S; Venkatesh J; Mondal A; Vhora I; Sau S; Muthu M; Polin LA; Levi E; Bepler G; Iyer AK; Singh M; Rishi AK
Oncotarget; 2018 Jul; 9(51):29680-29697. PubMed ID: 30038713
[TBL] [Abstract][Full Text] [Related]
3. Identification and Testing of Novel CARP-1 Functional Mimetic Compounds as Inhibitors of Non-Small Cell Lung and Triple Negative Breast Cancers.
Muthu M; Somagoni J; Cheriyan VT; Munie S; Levi E; Ashour AE; Yassin AE; Alafeefy AM; Sochacki P; Polin LA; Reddy KB; Larsen SD; Singh M; Rishi AK
J Biomed Nanotechnol; 2015 Sep; 11(9):1608-27. PubMed ID: 26485930
[TBL] [Abstract][Full Text] [Related]
4. Role of nano-lipid formulation of CARP-1 mimetic, CFM-4.17 to improve systemic exposure and response in osimertinib resistant non-small cell lung cancer.
Kommineni N; Nottingham E; Bagde A; Patel N; Rishi AK; Dev SRS; Singh M
Eur J Pharm Biopharm; 2021 Jan; 158():172-184. PubMed ID: 33220423
[TBL] [Abstract][Full Text] [Related]
5. Curcumol enhances the sensitivity of doxorubicin in triple-negative breast cancer via regulating the miR-181b-2-3p-ABCC3 axis.
Zeng C; Fan D; Xu Y; Li X; Yuan J; Yang Q; Zhou X; Lu J; Zhang C; Han J; Gu J; Gao Y; Sun L; Wang S
Biochem Pharmacol; 2020 Apr; 174():113795. PubMed ID: 31926937
[TBL] [Abstract][Full Text] [Related]
6. Dual-target MDM2/MDMX inhibitor increases the sensitization of doxorubicin and inhibits migration and invasion abilities of triple-negative breast cancer cells through activation of TAB1/TAK1/p38 MAPK pathway.
Fan Y; Li M; Ma K; Hu Y; Jing J; Shi Y; Li E; Dong D
Cancer Biol Ther; 2019; 20(5):617-632. PubMed ID: 30462562
[TBL] [Abstract][Full Text] [Related]
7. A CARP-1 functional mimetic loaded vitamin E-TPGS micellar nano-formulation for inhibition of renal cell carcinoma.
Cheriyan VT; Alsaab HO; Sekhar S; Stieber C; Kesharwani P; Sau S; Muthu M; Polin LA; Levi E; Iyer AK; Rishi AK
Oncotarget; 2017 Dec; 8(62):104928-104945. PubMed ID: 29285223
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of basal-like breast cancer growth by FTY720 in combination with epidermal growth factor receptor kinase blockade.
Martin JL; Julovi SM; Lin MZ; de Silva HC; Boyle FM; Baxter RC
Breast Cancer Res; 2017 Aug; 19(1):90. PubMed ID: 28778177
[TBL] [Abstract][Full Text] [Related]
9. Antagonists of anaphase-promoting complex (APC)-2-cell cycle and apoptosis regulatory protein (CARP)-1 interaction are novel regulators of cell growth and apoptosis.
Puliyappadamba VT; Wu W; Bevis D; Zhang L; Polin L; Kilkuskie R; Finley RL; Larsen SD; Levi E; Miller FR; Wali A; Rishi AK
J Biol Chem; 2011 Nov; 286(44):38000-38017. PubMed ID: 21903591
[TBL] [Abstract][Full Text] [Related]
10. CARP-1 functional mimetics: a novel class of small molecule inhibitors of medulloblastoma cell growth.
Ashour AE; Jamal S; Cheryan VT; Muthu M; Zoheir KM; Alafeefy AM; Abd-Allah AR; Levi E; Tarca AL; Polin LA; Rishi AK
PLoS One; 2013; 8(6):e66733. PubMed ID: 23826121
[TBL] [Abstract][Full Text] [Related]
11. The mitotic checkpoint is a targetable vulnerability of carboplatin-resistant triple negative breast cancers.
Moens S; Zhao P; Baietti MF; Marinelli O; Van Haver D; Impens F; Floris G; Marangoni E; Neven P; Annibali D; Sablina AA; Amant F
Sci Rep; 2021 Feb; 11(1):3176. PubMed ID: 33542435
[TBL] [Abstract][Full Text] [Related]
12. CARP-1 functional mimetics are a novel class of small molecule inhibitors of malignant pleural mesothelioma cells.
Jamal S; Cheriyan VT; Muthu M; Munie S; Levi E; Ashour AE; Pass HI; Wali A; Singh M; Rishi AK
PLoS One; 2014; 9(3):e89146. PubMed ID: 24598827
[TBL] [Abstract][Full Text] [Related]
13. Dual Inhibition of Key Proliferation Signaling Pathways in Triple-Negative Breast Cancer Cells by a Novel Derivative of Taiwanin A.
Kuo YH; Chiang EI; Chao CY; Rodriguez RL; Chou PY; Tsai SY; Pai MH; Tang FY
Mol Cancer Ther; 2017 Mar; 16(3):480-493. PubMed ID: 27956520
[TBL] [Abstract][Full Text] [Related]
14. Targeting SET to restore PP2A activity disrupts an oncogenic CIP2A-feedforward loop and impairs triple negative breast cancer progression.
Liu CY; Huang TT; Chen YT; Chen JL; Chu PY; Huang CT; Wang WL; Lau KY; Dai MS; Shiau CW; Tseng LM
EBioMedicine; 2019 Feb; 40():263-275. PubMed ID: 30651219
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of Notch1 reverses EMT and chemoresistance to cisplatin via direct downregulation of MCAM in triple-negative breast cancer cells.
Zeng D; Liang YK; Xiao YS; Wei XL; Lin HY; Wu Y; Bai JW; Chen M; Zhang GJ
Int J Cancer; 2020 Jul; 147(2):490-504. PubMed ID: 32020593
[TBL] [Abstract][Full Text] [Related]
16. BRCA1-IRIS inactivation overcomes paclitaxel resistance in triple negative breast cancers.
Blanchard Z; Paul BT; Craft B; ElShamy WM
Breast Cancer Res; 2015 Jan; 17(1):5. PubMed ID: 25583261
[TBL] [Abstract][Full Text] [Related]
17. CARP-1/CCAR1: a biphasic regulator of cancer cell growth and apoptosis.
Muthu M; Cheriyan VT; Rishi AK
Oncotarget; 2015 Mar; 6(9):6499-510. PubMed ID: 25894788
[TBL] [Abstract][Full Text] [Related]
18. The bromodomain inhibitor OTX015 (MK-8628) exerts anti-tumor activity in triple-negative breast cancer models as single agent and in combination with everolimus.
Vázquez R; Riveiro ME; Astorgues-Xerri L; Odore E; Rezai K; Erba E; Panini N; Rinaldi A; Kwee I; Beltrame L; Bekradda M; Cvitkovic E; Bertoni F; Frapolli R; D'Incalci M
Oncotarget; 2017 Jan; 8(5):7598-7613. PubMed ID: 27935867
[TBL] [Abstract][Full Text] [Related]
19. Triple negative breast cancers express receptors for LHRH and are potential therapeutic targets for cytotoxic LHRH-analogs, AEZS 108 and AEZS 125.
Seitz S; Buchholz S; Schally AV; Weber F; Klinkhammer-Schalke M; Inwald EC; Perez R; Rick FG; Szalontay L; Hohla F; Segerer S; Kwok CW; Ortmann O; Engel JB
BMC Cancer; 2014 Nov; 14():847. PubMed ID: 25410881
[TBL] [Abstract][Full Text] [Related]
20. The targeted inhibition of Hsp90 by a synthetic small molecule, DPide offers an effective treatment strategy against TNBCs.
Oh YJ; Park SY; Seo YH
Oncol Rep; 2018 Apr; 39(4):1775-1782. PubMed ID: 29436674
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
